Recent Subgroup Analyses from the CLEAR study in Advanced RCC
Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.
EP: 1.First-Line Treatments for Advanced Clear Cell RCC
EP: 2.Long-Term Follow-Up from CheckMate 214 in Advanced RCC
EP: 3.CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC
Now Viewing
EP: 4.Recent Subgroup Analyses from the CLEAR study in Advanced RCC
EP: 5.LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis
EP: 6.Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC
EP: 7.CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC
EP: 8.Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC
EP: 9.LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research
EP: 10.Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC
EP: 11.CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC
EP: 12.Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC
EP: 13.Clinical Insights on Belzutifan in Advanced RCC
EP: 14.Overview of Non–Clear Cell RCC
EP: 15.TKI Monotherapy Data in Non–Clear Cell RCC
EP: 16.KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC
EP: 17.Nivolumab Plus Cabozantinib in Non–Clear Cell RCC
EP: 18.Future Perspectives and Unmet Needs in Renal Cell Carcinoma
Related Videos
Related Content
